Inozyme Pharma, Inc. financial data

Symbol
INZY on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Summer Street, Suite 400, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Inozyme Pharma, LLC (to 1/5/2017)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.32K % +24.8%
Debt-to-equity 43.8 % +63.6%
Return On Equity -68.9 % -17.3%
Return On Assets -47.9 % -3.39%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.7M shares +1.63%
Common Stock, Shares, Outstanding 62.1M shares +33.8%
Entity Public Float 199B USD +155958%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 61.9M shares +38.1%
Weighted Average Number of Shares Outstanding, Diluted 61.9M shares +38.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 72.2M USD +45.7%
General and Administrative Expense 20.7M USD -4.42%
Operating Income (Loss) -92.9M USD -30.5%
Nonoperating Income (Expense) 4.33M USD +31%
Net Income (Loss) Attributable to Parent -88.6M USD -30.4%
Earnings Per Share, Basic -1.44 USD/shares 0%
Earnings Per Share, Diluted -1.44 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.2M USD -62.7%
Cash, Cash Equivalents, and Short-term Investments 145M USD +3.07%
Assets, Current 153M USD +6.53%
Property, Plant and Equipment, Net 1.13M USD -36.9%
Operating Lease, Right-of-Use Asset 853K USD -38.2%
Other Assets, Noncurrent 354K USD 0%
Assets 156M USD +3.17%
Accounts Payable, Current 3.53M USD +75.1%
Employee-related Liabilities, Current 3.84M USD +18.9%
Accrued Liabilities, Current 11.1M USD +20.1%
Liabilities, Current 15.5M USD +28.6%
Operating Lease, Liability, Noncurrent 419K USD -69.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 61.3M USD +35.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -103K USD -302%
Retained Earnings (Accumulated Deficit) -336M USD -35.7%
Stockholders' Equity Attributable to Parent 94.4M USD -10.6%
Liabilities and Equity 156M USD +3.17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.5M USD -38%
Net Cash Provided by (Used in) Financing Activities 159K USD -99.2%
Net Cash Provided by (Used in) Investing Activities 10.4M USD -24.5%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 62.1M shares +33.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 88.9M USD +42.3%
Deferred Tax Assets, Gross 89.3M USD +41.6%
Operating Lease, Liability 1.38M USD +176%
Payments to Acquire Property, Plant, and Equipment 32K USD -81.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -88.7M USD -31.5%
Lessee, Operating Lease, Liability, to be Paid 1.45M USD -40.9%
Property, Plant and Equipment, Gross 3.88M USD +3.44%
Operating Lease, Liability, Current 959K USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 944K USD -7.09%
Lessee, Operating Lease, Liability, to be Paid, Year One 944K USD -7.09%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 75K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 944K USD -7.09%
Deferred Tax Assets, Operating Loss Carryforwards 43M USD +19%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 410K USD -32.7%
Share-based Payment Arrangement, Expense 7.16M USD -4.01%
Interest Expense 1.4M USD +80.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%